IDR Data
CMS PUF data · 2023 Q1–2025 Q4

CPT 87181: Federal IDR outcomes

Evaluation of antimicrobial drug (antibiotic, antifungal, antiviral), agar dilution method

In 2025 Q1–Q4, the provider or facility offer prevailed in 76.7% of 202 determined Federal IDR dispute line items for CPT 87181. The median prevailing offer was 14.14x the QPA (25th–75th percentile 1.99x–24.62x; n = 117). The median time to a decision was 30 business days (n = 202).

Determined line items

202

2025 Q1–Q4 · 0 split decisions excluded

Provider win rate

76.7%

n = 202 · 2025 Q1–Q4

Median payment vs QPA

14.14x

middle half 1.99x–24.62x · n = 117 · 2025 Q1–Q4

Median days to decision

30

business days, from dispute initiation · n = 202 · 2025 Q1–Q4

Dollar amounts

Total awarded

$3,371

sum of prevailing offers · n = 54 · 2025 Q1–Q4

Total QPA

$818

sum of QPAs, same line items · n = 54 · 2025 Q1–Q4

Awarded above QPA

$2,553

total awarded minus total QPA · n = 54 · 2025 Q1–Q4

Median award per line item

$61

mean $62 · n = 54 · 2025 Q1–Q4

Median QPA

$7

per line item · n = 54 · 2025 Q1–Q4

Award vs QPA, dollar-weighted

4.12x

total awarded ÷ total QPA · n = 54 · 2025 Q1–Q4

Dollar amounts come from the separate CMS “QPA and Offers” file: line items decided for the provider or the plan with a non-suppressed QPA and prevailing offer. That file cannot be joined to the line items above, so its n differs. Awarded = the prevailing (selected) offer; it is not a record of what was paid. State comes from the file’s geographic region; a metro area that spans states counts in each. How the dollar figures work

Dollar amounts by period

PeriodLine items with $Total awardedTotal QPAAbove QPAMedian awardMedian QPAAward ×QPA ($-weighted)
2025 Q1–Q454$3,371$818$2,553$61$74.12x
2024 Q3–Q4Fewer than 30 line items with dollar amounts; not shown.
2024 Q3–2025 Q454$3,371$818$2,553$61$74.12x
2023 Q1–2024 Q2Not available (see methodology).

From the CMS QPA and Offers file (see above). Award ×QPA here is total awarded ÷ total QPA, so large claims weigh more than in the per-line median ratio.

By period

PeriodLine itemsWin %Median ×QPA25th–75thRatio nMedian days
2025 Q1–Q420276.7%14.14x1.99x–24.62x11730
2024 Q1–Q4Fewer than 30 determined line items; not shown.
2023 Q1–Q4Fewer than 30 determined line items; not shown.
2023 Q1–2025 Q421077.1%14.35x2.11x–24.57x122not pooled

Line items = determined dispute line items (n). Win rate excludes split decisions and includes default decisions. Ratio n = line items reporting a payment-to-QPA ratio. Days are business days as reported by CMS (2023–2024: from IDR entity assignment; 2025: from initiation) and are never pooled.

By state

State (place of service)Line itemsWin %Median ×QPARatio nMedian days
Texas19577.4%14.41x11530

2025 Q1–Q4 · rows with n ≥ 30 determined line items · sorted by n.

By specialty

Specialty groupLine itemsWin %Median ×QPARatio nMedian days
Emergency medicine and emergency departments16577.0%14.75x11430
Not reported / unspecified3476.5%–027.5

2025 Q1–Q4 · rows with n ≥ 30 determined line items · sorted by n.

Section: Pathology and laboratory (80047–89398)

FAQ

What is the Federal IDR provider win rate for CPT 87181?

In 2025 Q1–Q4, the provider or facility offer was selected in 76.7% of 202 determined dispute line items for CPT 87181. Split decisions are excluded from the denominator and default decisions are included. Withdrawn, settled and ineligible disputes are not in the CMS data.

How do Federal IDR payments compare with the QPA for CPT 87181?

In 2025 Q1–Q4, the median prevailing offer was 14.14x the qualifying payment amount (QPA), with a 25th to 75th percentile range of 1.99x to 24.62x (n = 117 line items). This uses the CMS field Prevailing Party Offer as % of QPA, where 1.00x equals the QPA.

How long do Federal IDR decisions take for CPT 87181?

In 2025 Q1–Q4, the median was 30 business days (n = 202 line items), using the CMS field Length of Time to Make Determination (from dispute initiation).

How to Utilize IDR